Celestra Inc. (KOSDAQ:352770)

Market Cap	13.46B
Revenue (ttm)	8.50B
Net Income (ttm)	-46.92B
Shares Out	2.56M
EPS (ttm)	-19,318.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	5,247.38
Previous Close	5,247.38
Day's Range	5,247.38 - 5,247.38
52-Week Range	487.00 - 33,975.00
Beta	1.15
RSI	45.80
Earnings Date	May 14, 2025

About Celestra

Celestra Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to preci...

• Industry: Medical Laboratories
• Founded: 2011
• Employees: 73
• Stock Exchange: KOSDAQ
• Ticker Symbol: 352770

Financial Performance

In 2024, Celestra's revenue was 8.50 billion, a decrease of -25.47% compared to the previous year's 11.41 billion. Losses were -46.92 billion, 11.0% more than in 2023.